White Papers

With sponsors having more oral solid dosage (OSD) products in their pipelines, CMOs anticipate an increasing trend in OSD outsourcing. Find out the criteria to choose the right CMO for OSD outsourcing.

Contract development manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly seek transparency and integrity in manufacturing data.

Explore how Cell and Gene, mRNA, Bispecifics, and ADCs are turning the tide as CDMOs see service demand for these therapies soar.

Outsourcing of bioanalytical lab services is set for explosive growth as the increasingly complex nature of modern-day therapeutics makes partnerships with CROs indispensable.

A number of CDMOs are accelerating their environmental drive as sustainability goals become one of the most urgent business strategies facing pharma companies today.

Read this White Paper on the ADC alternative that is capturing scientists’ imagination – antibody-linked PROTACs and the impact it could have in oncology, neurology, virology, and agriculture.

Read this white paper to gain insights about perceptions around integrated and standalone outsourcing. The white paper is based on surveys conducted across emerging biopharma, mid-size and large pharma in North America, Europe and other regions.

Understanding the many application areas of Hyaluronic acid in the cosmetic and pharma space, including possibilities for the future.